News & Events

Starting in April 2009 we increased our total space to 300 m2. Thanks to this expansion we could double our laboratory space. The operations in the new lab space were successfully started in May 2009.

We are proud to announce that in April 1st Dr. Armando Zuniga, formerly at Crucell / Berna Biotech, joined Redbiotec as Senior Scientist. With his strong background in pre-clinical development Dr. Zuniga is responsible for the veterinary business line and for the generation and validation of animal data of Redbiotec’s vaccine candidates.

On October 6 the Nobel Assembly in Sweden awarded half of the Nobel Prize in Physiology or Medicine 2008 to Harald Zur Hausen from Deutsches Krebsforschungszentrum (DKFZ).Redbiotec is developing improved vaccines against the Human Papilloma Virus using our unique expression technology for the production of complex virus-like particles.

Redbiotec recently added 3 new prominent members to our already outstanding advisory board. Among the new advisors is Dr. Reinhard Glück, president of the Swiss Biotech Association and Executive Vice President R&D, Vaccine Discovery, Crucell – Berna Biotech.

Recently, Redbiotec moved into the area of vaccine development by applying the unique expression technology to production of VLPs. To strengthen our position in this area, Dr. Sabine Wellnitz, formerly at Novartis and Roche, joined Redbiotec as a senior research scientist with a strong background in VLP production in insect cells.